This site is intended for healthcare professionals

Sign in
Go to /sign-in page

You can view 5 more pages before signing in

GISSI-3 trial

Authoring team

19394 patients who presented within 24 hr of the onset of symptoms of acute myocardial infarction were randomised to:

  • 6 weeks oral lisinopril vs. open control
  • nitrates (i.v. then transdermal) vs. open control

Other treatments, such as aspirin, beta-blockers and thrombolytics, were administered as clinically indicated.

Lisinopril was found to significantly reduce:

  • overall mortality at 6 weeks (odds ratio = 0.88)
  • severe ventricular dysfunction (odds ratio = 0.90)

Nitrates alone did not have a significant effect.

The combination of nitrates and lisinopril was slightly better than lisinopril alone in reducing:

  • overall mortality at 6 weeks (odds ratio = 0.83)
  • severe ventricular dysfunction (odds ratio = 0.85)

Reference:

  • GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. (1994). Lancet, 343, 1115-22.
  • Eisenberg PR (1996). Early treatment with lisinopril for 6 weeks reduced mortality at 6 months in acute MI. EBM, 1 (5), 139.

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.